ReCode Therapeutics’ Post

Exciting news! We have officially dosed the first patient in our Phase 1b clinical study of RCT2100, an investigational inhaled mRNA therapy for people with cystic fibrosis (CF). This marks an important step toward offering a potential new treatment to those in the CF who are still in need of options. Formulated using our Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform, RCT2100 is designed to target the root cause of CF by delivering CFTR mRNA directly to the lungs, aiming to restore CFTR protein function, potentially benefiting more people living with CF. At ReCode, we’re harnessing precision delivery to power the next wave of mRNA and gene correction therapeutics. Learn more: https://lnkd.in/gw-T-kh7

This World Mental Health Day, we emphasize mental health as a fundamental human right, with a focus on this year's theme: "It is Time to Prioritize Mental Health in the Workplace." As we carry out our professional duties, it's essential to recognize that everyone deserves access to the highest standard of mental health care. No one should face exclusion or be deprived of mental healthcare. Worldwide, too many people encounter barriers to quality care and suffer from discrimination. Let today serve as a reminder. We must commit to advocating for mental health today and every day. By prioritizing mental health in our workplaces, we contribute to a more inclusive, supportive environment for all. #WorldMentalHealthDay #MentalHealthDay #MentalHealth

At ReCode Therapeutics, we're developing a potential new treatment for Primary Ciliary Dyskinesia (PCD). Currently, there are no approved treatments for PCD. This investigational mRNA-based therapeutic targets PCD caused by mutations in the DNAI1 gene. This gene is crucial for ciliary movement. By delivering it as an inhaled therapy, we aim to restore ciliary function in the lungs of affected individuals, addressing the root cause of PCD rather than merely managing symptoms. For more information about this potential new treatment, and to learn if you’re eligible to participate in an upcoming UK clinical study, visit: https://lnkd.in/gAVUdG-p #PCD #GeneticMedicines #PatientsFirst #PrimaryCiliaryDyskinesia #PCDAwarenessMonth

Over 90% of PCD patients are eager for new treatment options—are you aware of the challenges they face? In partnership with the PCD Foundation, we surveyed the PCD community and discovered a powerful demand for innovative therapies. But what exactly is primary ciliary dyskinesia (PCD)? PCD is a rare genetic disorder that impacts the cilia—tiny, hair-like structures that help keep the airways, ears, and other parts of the body functioning. When these cilia can't move properly, it leads to chronic respiratory infections, ear infections, and even fertility issues. Shockingly, there are still no approved treatments for this life-altering condition. Raising awareness of PCD is crucial for early diagnosis, better care, and accelerating the development of much-needed treatments. That’s why we’re dedicated to creating innovative therapies to meet the needs of this resilient community. Learn more about our commitment to PCD patients: https://recodetx.com/pcd/ Connect with the PCD Foundation and discover more about their work here: https://pcdfoundation.org/ Source: PCD Foundation Participation in Research Survey #mRNATherapy #PCD #GeneticMedicines #PatientsFirst #PrimaryCiliaryDyskinesia #PCDAwarenessMonth

At ReCode we enjoy prioritizing our connections with and supporting the patient community. Recently, we joined our close collaborators — PCD Support UK, Emily's Entourage and the Cystic Fibrosis Research Institute — at annual events highlighting important research progress for #PCD and #CF. We are grateful for their continued commitment to patients and support for ReCode.

October is #PCDAwarenessMonth—a time to shine a light on #PrimaryCiliaryDyskinesia (PCD), a rare genetic disorder where tiny cilia in the body don’t function as they should. For those living with PCD, this means a lifetime of respiratory challenges and ongoing health complications. We are proud to support and collaborate with advocacy groups like the PCD Foundation to drive change. Together, we’re pushing for earlier diagnosis, better care, and advancing research that could unlock life-changing treatments. Swipe to learn more about this #raredisease. #PCD #GeneticMedicines #PatientsFirst

Today, ReCode announced two additions to its Scientific Advisory Board (SAB) that will further deepen the company’s expertise in gene correction and mRNA drug discovery. The company has appointed Andrew Bellinger, M.D., Ph.D., and the 2023 Nobel Prize in Physiology or Medicine recipient Katalin Karikó, Ph.D. Read more about the SAB appointees: https://lnkd.in/gteQepsm

We are honored to have spoken with Mel and Kate Kotlyar about their journey with cystic fibrosis and the hope they find in clinical trials. For Mel, "There is only a future for the cure through clinical trials... it's the only way." His powerful, declarative words remind us how vital these studies are - not just for CF - but for anyone affected by a genetic disease. Every trial is a step toward potential therapies that could benefit many lives. Diagnosed at just 15 months old, Mel has faced immense challenges, but he remains optimistic and focused on making an impact through his participation in clinical trials. His resilience inspires our mission to develop new therapeutic options: "Don't lose hope. Brilliant people and amazing companies are dedicated to finding a cure for those left out [of treatment options]." At ReCode, we are proud to be advancing this mission through our Phase 1b clinical study of RCT2100, an investigational inhaled mRNA therapy for CF, designed for people like Mel who have limited treatment options. Thank you, Mel and Kate, for sharing your inspiring story. Like them, we dare to dream of a world where CF is conquered for all.

ReCode CEO, Dr. Shehnaaz Suliman, shares an important message about our newly initiated Phase 1b clinical trial for RCT2100, a novel therapeutic for people with cystic fibrosis. In this video, Dr. Suliman discusses how patients without current treatment options can get involved and help advance new therapies. Watch below to learn how you can be part of this journey.

Today at the North American Cystic Fibrosis Conference (NACFC) in Boston, we presented promising preclinical data from our mRNA-based cystic fibrosis program. This data highlighted the potential of RCT2100 to offer a new therapeutic option for those living with CF. For those affected by CF who have run out of treatment options, our commitment remains strong: no one should be left behind. Through scientific innovation, we aim to create a real and lasting impact for the CF community. Read more about the news here: https://lnkd.in/gD4AEceV